Literature DB >> 8353232

Forty years of meningococcal disease in Israel: 1951-1990.

C Block1, M Roitman, B Bogokowsky, S Meizlin, P E Slater.   

Abstract

Meningococcal disease accounts for approximately 20% of cases of bacterial meningitis in Israel. During the period 1951-1990, the annual incidence of meningococcal disease rarely exceeded two cases per 100,000 persons and was generally higher among non-Jews (largely the Arab population) than among Jews; there were some notable peaks of disease activity during 1963-1967, 1975, and 1987-1988. The highest incidence was among infants and young children, with a slight male predominance. The main period of disease activity was from January to April, but an unusual secondary peak in July coincided with the onset of peak summer temperatures. Monthly disease frequencies were significantly correlated with relative humidity. Incidence rates varied between regions and were lower in cities than in smaller settlements. Overall case-fatality rates decreased to approximately 11% for the period 1981-1990. Outbreaks were infrequent and tended to be small. Meningococci of serogroup B have dominated since the mid-1970s. Group A meningococci were isolated significantly more commonly from Arabs (26.26%) than from Jews (1.03%; P < .000001). The frequency with which group A organisms occurred among clinical isolates appeared to follow a more or less cyclical pattern.

Entities:  

Mesh:

Year:  1993        PMID: 8353232     DOI: 10.1093/clinids/17.1.126

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Evidence for indirect nosocomial transmission of Neisseria meningitidis resulting in two cases of invasive meningococcal disease.

Authors:  Johannes Elias; Heike Claus; Matthias Frosch; Ulrich Vogel
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

2.  First recorded outbreaks of meningococcal disease in the Israel Defence Force: three clusters due to serogroup C and the emergence of resistance to rifampicin.

Authors:  R Almog; C Block; M Gdalevich; B Lev; M Wiener; S Ashkenazi
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

3.  Respiratory virus infection and risk of invasive meningococcal disease in central Ontario, Canada.

Authors:  Ashleigh R Tuite; Laura M Kinlin; Stefan P Kuster; Frances Jamieson; Jeffrey C Kwong; Allison McGeer; David N Fisman
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

4.  Invasive meningococcal disease in children in Jerusalem.

Authors:  C Stein-Zamir; N Abramson; G Zentner; H Shoob; L Valinsky; C Block
Journal:  Epidemiol Infect       Date:  2007-07-30       Impact factor: 2.451

5.  A cluster of invasive meningococcal disease revealed by the characterization of a novel serogroup B meningococcal clone.

Authors:  L Valinsky; J Jaffe; N Keller; C Block; N Abramson; C Stein-Zamir
Journal:  Epidemiol Infect       Date:  2015-06-26       Impact factor: 4.434

6.  Climate, demographic factors and geographical variations in the incidence of invasive meningococcal disease in Italy.

Authors:  F Vescio; L Busani; L Mughini Gras; C Fazio; A Neri; L Avellis; G Rezza; P Stefanelli
Journal:  Epidemiol Infect       Date:  2014-10-13       Impact factor: 4.434

7.  Serogroup A Neisseria meningitidis with reduced susceptibility to ciprofloxacin.

Authors:  Jacob Strahilevitz; Amos Adler; Gillian Smollan; Violeta Temper; Nathan Keller; Colin Block
Journal:  Emerg Infect Dis       Date:  2008-10       Impact factor: 6.883

8.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

9.  Spatiotemporal analysis of invasive meningococcal disease, Germany.

Authors:  Johannes Elias; Dag Harmsen; Heike Claus; Wiebke Hellenbrand; Matthias Frosch; Ulrich Vogel
Journal:  Emerg Infect Dis       Date:  2006-11       Impact factor: 6.883

10.  Environmental exposures and invasive meningococcal disease: an evaluation of effects on varying time scales.

Authors:  Laura M Kinlin; C Victor Spain; Victoria Ng; Caroline C Johnson; Alexander N J White; David N Fisman
Journal:  Am J Epidemiol       Date:  2009-01-22       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.